ABCL stock forecast 2025 probability charts highlight two main scenarios: a bullish path towards $14 if key pipeline progresses, and a bearish fallback near $7 if trial readouts underperform. Risk-adjusted strategies recommend position sizing accordingly. The general public-- including retail investors -- own 32% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies. To track analyst ratings and price targets for AbCellera Biologics, check out Quiver Quantitative's $ABCL forecast page. Chart-based ABCL stock forecast 2025 suggests an ascending triangle pattern forming, often interpreted as bullish in technical analysis. Maintaining price above $8 support is critical for sustaining this formation into next year.